Tuberc Respir Dis.  2008 Jan;64(1):44-47. 10.4046/trd.2008.64.1.44.

Gefitinib-induced Acute Fatal Respiratory Failure in a Woman who Never Smoked and had Adenocarinoma of the Lung with EGFR Mutation

• Kim SG
• Ryu JS
• Han JY
• Kim HJ
• Cho JH
• Kwak SM
• Lee HL

• KMID: 1478141
• DOI: http://doi.org/10.4046/trd.2008.64.1.44

Abstract

No abstract available.

Keyword

Acute respiratory failure; Gefitinib; Lung cancer

MeSH Terms

Female
Humans
Lung
Lung Neoplasms
Quinazolines
Respiratory Insufficiency
Smoke
Quinazolines
Smoke

Figure

• 

  Figure 1 At the time of diagnosis, bilateral multiple lung nodules, right pleural effusion and a mass at the superior segment of the left lower lobe were observed on chest PA (A) and chest CT scans (B, C). At the 17th day after gefitinib was administered, the multiple lung nodules, pleural effusion and lung mass were shown to be decreased in size on the chest AP (D) and on similar slices from the pulmonary embolus protocol CT scan (E, F) while diffuse ground glass opacities were newly developed in both lungs.

• 

  Figure 2 The in-frame deletion mutation in codon 746-750 of exon 19 was noted on the EGFR mutation analysis.

Reference

1. Ando M, Okamoto I, Yamamoto N, Takeda K, Tamura K, Seto T, et al. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol. 2006. 24:2549–2556.

2. Cohen MH, Williams GA, Sridhara R, Chen G, McGuinn WD Jr, Morse D, et al. United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res. 2004. 10:1212–1218.

3. Takano T, Ohe Y, Kusumoto M, Tateishi U, Yamamoto S, Nokihara H, et al. Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib. Lung Cancer. 2004. 45:93–104.

4. Fujiwara Y, Kiura K, Toyooka S, Takigawa N, Tokumo M, Hotta K, et al. Relationship between epidermal growth factor receptor gene mutations and the severity of adverse events by gefitinib in patients with advanced non-small cell lung cancer. Lung Cancer. 2006. 52:99–103.

5. Seto T, Seki N, Uematsu K, Tanigaki T, Shioya S, Koboyashi T, et al. Gefitinib-induced lung injury successfully treated with high-dose corticosteroids. Respirology. 2006. 11:113–116.

6. Ohyanagi F, Ando Y, Nagashima F, Narabayashi M, Sasaki Y. Acute gefitinib-induced pneumonitis. Int J Clin Oncol. 2004. 9:406–409.

7. Inoue A, Saijo Y, Maemondo M, Gomi K, Tokue Y, Kimura Y, et al. Severe acute interstitial pneumonia and gefitinib. Lancet. 2003. 361:137–139.

8. Rabinowits G, Herchenhorn D, Rabinowits M, Weatge D, Torres W. Fatal pulmonary toxicity in a patient treated with gefitinib for non-small cell lung cancer after previous hemolytic-uremic syndrome due to gemcitabine. Anticancer Drugs. 2003. 14:665–668.

9. Ieki R, Saitoh E, Shibuya M. Acute lung injury as a possible adverse drug reaction related to gefitinib. Eur Respir J. 2003. 22:179–181.

10. Okamoto I, Fujii K, Matsumoto M, Terasaki Y, Kihara N, Kohrogi H, et al. Diffuse alveolar damage after ZD1839 therapy in a patient with non-small cell lung cancer. Lung Cancer. 2003. 40:339–342.

11. Inomata S, Takahashi H, Nagata M, Yamada G, Shiratori M, Tanaka H, et al. Acute lung injury as an adverse event of gefitinib. Anticancer Drugs. 2004. 15:461–467.

12. Nagaria NC, Cogswell J, Choe JK, Kasimis B. Side effects and good effects from new chemotherapeutic agents. Case 1. Gefitinib-induced interstitial fibrosis. J Clin Oncol. 2005. 23:2423–2424.

13. Sumpter K, Harper-Wynne C, O'Brien M, Congleton J. Severe acute interstitial pnuemonia and gefitinib. Lung Cancer. 2004. 43:367–368.

14. Suzuki H, Aoshiba K, Yokohori N, Nagai A. Epidermal growth factor receptor tyrosine kinase inhibition augments a murine model of pulmonary fibrosis. Cancer Res. 2003. 63:5054–5059.

15. Ishii Y, Fujimoto S, Fukuda T. Gefitinib prevents bleomycin-induced lung fibrosis in mice. Am J Respir Crit Care Med. 2006. 174:550–556.